

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Corporate Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
<http://www.daiichisankyo.com>

Daiichi Sankyo Launches New Generic Drugs Through Its Daiichi Sankyo Espha Subsidiary

Tokyo, Japan (June 20, 2014) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that its Japan generics subsidiary, Daiichi Sankyo Espha, today launched six new generic drugs with three new active ingredients.

Overview

1. Product names/therapeutic categories

Product name	Therapeutic category	Original brand name
Valsartan Tablets 20mg “DSEP”	Selective AT ₁ receptor Blocker	Diovan® Tablets 20mg, 40mg, 80mg, 160mg
Valsartan Tablets 40mg “DSEP”		
Valsartan Tablets 80mg “DSEP”		
Valsartan Tablets 160mg “DSEP”		
Losarhyd Combination Tablets LD “EP” (Losartan Potassium+ Hydrochlorothiazide Tablets)	Prolonged ARB/Diuretic combination	Preminent® Combination Tablets LD
Imatinib Tablets 100mg “DSEP”	Anti-malignant tumor agent	Gleevec® Tablets 100mg

2. Product attributes

Daiichi Sankyo Espha has created innovative labeling on tablets and PTP sheets to prevent medical error and improve ease of use and hails these value added generics as “premium generics.”

Tablets

- Printing on tablets (Valsartan Tablets / Losarhyd Combination Tablets LD)
The product name, dosage per tablet and company name will be printed on both sides to be easily distinguishable.
- Improvement of tablet separation (Valsartan Tablets)
Change to form of secant line on front of tablets which makes them easier to break up.
- Improvement to way of taking tablets (Imatinib Tablets)
Reduction in size of tablets (by 17%) which makes them easier to swallow.

PTP packaging

- Pitch control (fixed position printing/both sides of the tablet) for all new items
Through pitch control, it is possible to display the product name and dosage on each pocket of PTP sheets, making it easier for patients to recognize the pill even if it is taken out of the PTP sheet.
- Design that allows for easy identification for all new items
Special markings on both sides of the PTP sheets allow for improved identification.
- GS1 data barcode for all new items
The GS1 data barcode is marked on each pocket of PTP sheets to prevent medication errors.

Images of DSEP tablets and PTP sheets

Valsartan Tablets 80mg “DSEP”



Losarhyd Combination Tablets LD “EP”



Imatinib Tablets 100mg “DSEP”



About Daiichi Sankyo Espha

Daiichi Sankyo Espha was created in April 2010 to manufacture and market generic drugs and accommodate rising demand based on the spirit of the Daiichi Sankyo Group corporate philosophy* of supplying pharmaceuticals to address diverse medical needs. Daiichi Sankyo Espha strives to provide pharmaceuticals that provide peace of mind for users by fulfilling the most important pharmaceutical criteria of quality, information, and stable supply while delivering the economic benefits of generics.

Daiichi Sankyo Espha Company Overview

Company name: Daiichi Sankyo Espha Co., Ltd.

Established: April 1, 2010

Business: Manufacture and sale of pharmaceuticals

Capital: 450 million yen

Representative: President Hiroto Yoshiwaka

Headquarters: 3-5-1, Nihonbashi, Honcho, Chuo-ku, Tokyo

*Daiichi Sankyo Group corporate philosophy

To contribute to the enrichment of quality of life around the world through the creation of innovative pharmaceuticals, and through the provision of pharmaceuticals addressing diverse medical needs.